Raynaud's phenomenon supplement protocol — what the evidence shows for vasospasm
Raynaud's phenomenon is episodic vasospasm of the digital arteries causing the characteristic colour change (white → blue → red) in fingers and toes, triggered by cold or stress. Primary Raynaud's (no underlying disease) is common and usually mild; secondary Raynaud's accompanies connective tissue diseases — scleroderma, lupus, mixed connective tissue disease — and is more severe with risk of digital ulceration and ischaemic damage. Conservative measures and, when needed, calcium channel blockers dominate the management; the supplement layer is small and adjunctive.
What actually has trial evidence
Omega-3 EPA/DHA
3–4 g EPA+DHA combined/day; 12-week trial
The DiGiacomo 1989 trial showed reduced frequency and severity of Raynaud's attacks with high-dose fish oil (12 g/day). Subsequent smaller trials are mixed but generally favourable, particularly in primary Raynaud's. Mechanism involves prostaglandin balance and modest vasodilatory effects. At pharmacological doses (3 g+/day), discuss with cardiology if on anticoagulants or with atrial fibrillation history — high-dose omega-3 has an emerging AF signal.
Ginkgo biloba (EGb 761 standardised extract)
120 mg b.i.d. standardised EGb 761
Small RCTs (Muir 2002 and others) show reductions in attack frequency in primary Raynaud's. Effect size is modest. Caution in users on anticoagulants or with bleeding risk; theoretical interaction. Reasonable as an adjunct after omega-3 trial.
L-Citrulline (preferred over L-arginine)
3–6 g L-citrulline/day in divided doses
L-arginine has been studied at high doses in Raynaud's with mixed results; oral arginine has poor bioavailability due to first-pass arginase metabolism. L-citrulline bypasses this issue. The vasodilation mechanism (raised NO substrate) is reasonable but RCT evidence specifically in Raynaud's is sparse. Reasonable as an experimental adjunct in users who haven't responded to omega-3 and conservative measures.
Vitamin D3 (in deficiency)
2,000–4,000 IU/day to a 25-OH-D target of 30–50 ng/mL
Some observational association between low vitamin D status and Raynaud's; small interventional trials show modest improvement on supplementation in deficient users. Test 25-OH-D before supplementing routinely.
What dominates over supplements — the actual management
- Cold avoidance and warming — gloves, hand warmers, layered clothing, warm water immersion at onset of attack. Mittens warmer than gloves. Heated insoles for feet. Whole-body warmth matters as much as hand warmth (peripheral vasoconstriction is centrally driven).
- Smoking cessation and avoidance of secondhand smoke — nicotine is a potent vasoconstrictor and worsens Raynaud's.
- Beta-blocker review — non-selective beta-blockers (propranolol) commonly worsen Raynaud's; alternative antihypertensives may be needed. Discuss with prescriber if BP medication is in use.
- Calcium channel blockers (prescription) — first-line pharmacotherapy when conservative measures are inadequate. Nifedipine extended-release (30–60 mg/day) and amlodipine are commonly used. Side effects: ankle oedema, headache, flushing.
- Stress management — emotional stress triggers attacks; CBT and relaxation techniques have modest evidence.
- Caffeine reduction — sympathomimetic effects can worsen vasospasm in sensitive users.
- For severe or secondary Raynaud's: PDE5 inhibitors (sildenafil), prostaglandin analogues (iloprost), endothelin receptor antagonists (bosentan) for digital ulcers — all under rheumatology guidance.
What to skip
- "Circulation" multivitamins with niacin flush as a feature — niacin flush is brief and uncontrolled; not a treatment for Raynaud's-style vasospasm. Niacin's own cardiovascular evidence has been disappointing.
- Cayenne / capsaicin oral supplements — topical capsaicin has analgesic uses but oral supplementation lacks Raynaud's-specific RCT evidence.
- High-dose vitamin E — old hypothesis; no convincing trial evidence; large doses have bleeding risk.
- Magnesium for Raynaud's specifically — modest theoretical mechanism; no convincing Raynaud's-specific RCT evidence.
- "Cold therapy" trendy supplements — no Raynaud's evidence.
- Cannabis / CBD products for Raynaud's — no evidence; theoretical vasoactive effects unclear.
What to track
Attack frequency (per week) and duration (per attack), severity (Raynaud's Condition Score), and any ulceration episodes are the standard outcome measures. Pictures of attacks are useful in clinical evaluation. Reassess at 12 weeks of supplement intervention. If attacks remain frequent or severe, pharmacotherapy escalation under prescribing clinician.